Dr Michael Lichtenberg today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22

HORSHAM, UK – 01 Nov 2022 – Veryan Medical Ltd announces that Dr Michael Lichtenberg (Klinikum Hochsauerland, Arnsberg, Germany) today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22 in the Late Breaking Clinical Trials session at VIVA 2022 in Las Vegas, US.

Download pdf – Veryan Medical MIMICS 3D VIVA 22 Press Release

BioMimics 3D Vascular Stent System has FDA and CE Mark approval.
BioMimics 3D & Swirling Flow Stent are registered trademarks of Veryan Medical Limited.
Veryan Medical Limited is a member of the Otsuka Medical Devices group of companies.
CAUTION: Federal law restricts this device to sale by or on the order of a physician.

PAM 14 Version 3.0